USO 22002
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Disease Types: Solid Tumors Research
Eligibility Requirements:
- Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.
- Recovery to baseline or < Grade 1 CTCAE v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
- Karnofsky Performance Status (KPS) >= 70%.
- Adequate organ and marrow function.
- Sexually active fertile subjects and partner agree to use highly effective methods of contraception.
- Female subjects of childbearing potential must not be pregnant at screening.
Available at: